Brenda M. Sandmaier, MD, of Fred Hutchinson Cancer Research Center, and Sagar Lonial, MD, of Emory University, discuss study findings on sirolimus combined with mycophenolate mofetil and cyclosporine to improve prevention of acute graft-vs-host-disease after unrelated hematopoietic cell transplantation (Abstract 506).
Jean M. Connors, MD, of Brigham and Women’s Hospital, and Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discuss a roundup of key findings on a critical area in the treatment of hematologic malignancies (Abstracts 17, 85, 86, 135, 139, 143, 273, 415, 419, 719, 877, 880).
“Whether or not individual professionals support the clinical use of herbal cannabis, all clinicians will encounter patients who elect to use it and therefore need to be prepared to advise them on cannabis-related clinical issues despite limited evidence to guide care,” according to a recently...
With reports about new marijuana dispensaries sprouting up as more states approve the legal use of medical marijuana, and patients and family members questioning how to get it, medical marijuana is a “topic you can’t escape,” noted Judith A. Paice, PhD, RN.1 Dr. Paice is Director of the Cancer...
Chemotherapy-induced peripheral neuropathy is a common side effect of cancer treatment—the incidence is reported to be as high as 70% in the first month of chemotherapy1—and can cause significant disability in patients. The extent of the neurotoxicity incurred by patients varies depending on the...
As cancer therapies improve and the population as a whole increases, there are rising numbers of elderly patients with cancer. More than half of patients newly diagnosed with cancer are aged 65 years or older.1 In January 2012, it was estimated that more than 8 million cancer survivors were over...
Patients with disseminated advanced cancer who undergo surgery are far more likely to endure long hospital stays and readmissions, referrals to extended care facilities, and death, University of California (UC) Davis researchers have found. Their study, published by Bateni et al in PLOS One,...
Dexamethasone mouth rinse should be given prophylactically to prevent stomatitis associated with everolimus (Afinitor)/exemestane in metastatic breast cancer, according to Hope S. Rugo, MD, principal investigator of the SWISH trial and Director of Breast Oncology and Clinical Trials Education at...
With checkpoint inhibitors in frequent use, clinicians strive daily to balance the efficacy and toxicity of these treatments. At the 2016 Palliative Care in Oncology Symposium, Lynn M. Schuchter, MD, FASCO, the C. Willard Professor of Hematology-Oncology at the University of Pennsylvania,...
In a two-institution experience reported in the Journal of Clinical Oncology, Naidoo et al identified the incidence of pneumonitis occurring in patients receiving anti–PD-1/PD-L1 (programmed cell death protein 1/ligand 1) monoclonal antibody as monotherapy or combined with anticytotoxic...
According to a phase III trial reported by Navari et al in The New England Journal of Medicine, the addition of the antipsychotic agent olanzapine vs placebo to dexamethasone, aprepitant, or fosaprepitant, and a 5-hydroxytryptamine type 3–receptor antagonist reduced nausea and improved antiemetic...
Stephen T. Sonis, DMD, DMSc, of Dana-Farber Cancer Institute, discusses the epidemiology, pathogenesis, and scope of oral complications of radiation therapy.
Joseph A. Greer, PhD, of Massachusetts General Hospital, discusses the development of a mobile application to address treatment adherence and symptoms (Abstract 104).
Tracy A. Balboni, MD, MPH, of the Dana-Farber Cancer Institute, talks about how to preserve quality of life in the presence of complex spinal lesions, including novel ways to assess spinal instability and treat metastases.
The U.S. Food and Drug Administration (FDA) has approved an extended-release version of granisetron (Sustol) for the prevention of chemotherapy-induced nausea and vomiting, according to a news release by Heron Therapeutics, the drug’s manufacturer. Granisetron is an extended-release, injectable...
Hair loss can be a devastating side effect of chemotherapy, but the recent U.S. Food and Drug Administration (FDA) approval of the DigniCap Cooling System and the growing acceptance of scalp-cooling methods in the United States may improve the quality of life for many patients receiving...
Heron Therapeutics, Inc, announced on August 10, 2016, that the U.S. Food and Drug Administration (FDA) has approved granisetron (Sustol) extended-release injection. Granisetron is a serotonin-3 (5-HT3) receptor antagonist indicated in combination with other antiemetics in adults for the prevention ...
Management of chemotherapy-induced vomiting has improved with the use of antiemetics, but chemotherapy-induced nausea remains a major clinical problem, according to Alex Molassiotis, RN, PhD, Professor and Head of the School of Nursing at The Hong Kong Polytechnic University. And, he added, the...
Prophylactic use of dexamethasone mouthwash significantly minimized the incidence of all grades of stomatitis in postmenopausal women receiving everolimus (Afinitor, Zortress) and exemestane for the treatment of hormone receptor–positive metastatic breast cancer, according to data presented by...
Chemotherapy- and radiotherapy-induced gastrointestinal (GI) toxicities have risen alongside improved survival rates for many cancers, according to Jervoise Andreyev, MA, PhD, Consultant Gastroenterologist in GI Consequences of Cancer Treatment at the Royal Marsden Hospital in London. “For every...
In a phase III trial reported by Navari et al in The New England Journal of Medicine, the addition of the antipsychotic agent olanzapine vs placebo to dexamethasone, aprepitant, or fosaprepitant, and a 5-hydroxytryptamine type 3–receptor antagonist reduced nausea and improved antiemetic...
Self-administered relaxing acupressure and stimulating acupressure were both associated with reduced persistent fatigue vs usual care in breast cancer survivors, according to a randomized clinical trial reported by Zick et al in JAMA Oncology. However, only relaxing acupressure had significant...
A receptor protein that is the target of the breast cancer drug trastuzumab (Herceptin) is needed for proper heart blood vessel development, reported researchers from the Perelman School of Medicine at the University of Pennsylvania, Philadelphia. They published their findings this month in a paper ...
In a study reported in the Journal of Clinical Oncology, Laird et al found that increased systemic inflammation was associated with poorer patient-reported quality of life independent of performance status. Study Details The study involved data from 2,520 adult patients in a biobank of patients...
Observational Study Title: Assessment for Long-Term Cardiovascular Impairment Associated With Trastuzumab Cardiotoxicity in HER2-Positive Breast Cancer Survivors Study Type: Observational Study Sponsor and Collaborators: Memorial Sloan Kettering Cancer Center Purpose: To study whether strain and...
In an analysis of the linked Southwest Oncology Group–Medicare databases reported by Hershman et al in the Journal of Clinical Oncology, an increased risk of peripheral neuropathy in older patients receiving taxane therapy was associated with increasing age and a history of diabetes in...
Fatigue and sleep disruption are common occurrences for most patients diagnosed with cancer. Simply having a serious physical illness like cancer along with its associated pain, hospitalization, and treatment, as well as the attendant psychological impact, all contribute to the onset of fatigue...
A new study published by Kariminia et al in the journal Blood has identified a protein that could diagnose chronic graft-vs-host disease in patients undergoing blood and bone marrow transplantation. The work was led by researchers in the Michael Cuccione Childhood Cancer Research Program at BC...
A mindfulness-based stress-reduction program for breast cancer survivors was associated with psychological and physical symptom benefits during and at 6 weeks after intervention, according to a randomized trial reported in the Journal of Clinical Oncology by Lengacher et al. Study Details In the...
Hurria et al validated a prediction tool for chemotherapy toxicity in cancer patients aged ≥ 65 years in an external cohort, according to a report in the Journal of Clinical Oncology. The predictive model had been developed in a prior study in 500 patients. Study Details The study...
This past January, ASCO held its inaugural Cancer Survivorship Symposium, which brought together the fields of medical oncology and primary care to address the critical need for coordinated care for cancer survivors. Among the presenters at the symposium was Smita Bhatia, MD, MPH, who gave the...
In the Clinic provides overviews of novel oncology agents, addressing indications, mechanisms, administration recommendations, safety profiles, and other essential information needed for the appropriate clinical use of these drugs. On March 30, 2016, defibrotide sodium (Defitelio) was approved for...
Loss of appetite during illness is a common and potentially debilitating phenomenon. In cancer patients especially, it can even shorten lifespan. Scientists at The Scripps Research Institute (TSRI) have discovered how an immune system molecule controls a brain circuit and reduces appetite. Their...
In an Italian trial reported in the Journal of Clinical Oncology, Lesi et al found that the addition of acupuncture to enhanced self-care improved hot flashes, climacteric symptoms, and quality-of-life measures in women with breast cancer. Study Details In the trial, 190 women were randomized to...
While stem cells have shown promise for treating brain regions damaged by cancer radiation treatments, University of California, Irvine (UCI) researchers have found that microscopic vesicles isolated from these cells provide similar benefits without some of the risks associated with stem cells....
Joseph B. Narus, DNP, GNP-BC, ANP, of Memorial Sloan Kettering Cancer Center, discusses the impact of cancer treatment on men’s sexual health, and treatment options to improve erectile function.
On March 30, 2016, the U.S. Food and Drug Administration (FDA) approved defibrotide sodium (Defitelio) for the treatment of adult and pediatric patients with hepatic veno-occlusive disease, also known as sinusoidal obstructive syndrome, with renal or pulmonary dysfunction following hematopoietic...
Dignitana Inc. announced today that the DigniCap scalp cooling system, which was cleared by the U.S. Food and Drug Administration (FDA) in December 2015 to effectively reduce the likelihood of chemotherapy-induced hair loss in women with breast cancer, is now available at 10 cancer treatment...
A quality improvement initiative to reduce the reliance of patients on visits to the emergency department for treatment of side effects related to cancer treatment was reported to be highly effective, according to early findings from a new study. 1 The strategy, involving a telephone triage...
Venous thromboembolic events are more prevalent in patients with cancer than in persons without it. Cancer is associated with a high rate of venous thromboembolism recurrence, bleeding, requirement for long-term anticoagulation, and reduced quality of life. Moreover, thrombosis is the second most...
A new study from The University of Texas MD Anderson Cancer Center evaluating the use of neurofeedback found a decrease in the experience of chronic pain and an increase in quality of life among patients with neuropathic pain. The study was presented at the annual meeting of the American...
The addition of fosaprepitant (Emend) to palonosetron and dexamethasone reduced the risk of emesis during 5 weeks of chemoradiotherapy for cervical cancer, according to the phase III GAND-emesis trial reported in The Lancet Oncology by Ruhlmann et al. Study Details In the double-blind trial, 234...
Here are several more abstracts selected from the proceedings of the 2015 American Society of Hematology (ASH) Annual Meeting and Exposition, focusing on the topic of anticoagulation and the cancer patient. For other selected abstracts from this conference, see the December 25, 2015, and the...
Although chemotherapy is often cited as the main culprit for diminishing cognitive function in patients with cancer, ushering the term “chemobrain” into the vernacular, research by Tim A. Ahles, PhD, and his colleagues is showing that multiple factors may contribute to the condition.1 Using breast...
Mario E. Lacouture, MD, of Memorial Sloan Kettering Cancer Center, discusses the effect on patients of dermatologic toxicities associated with targeted therapies: their psychosocial impact, financial burden, physiological pain, and potential to alter therapy. But the side effects of targeted treatments can and should be addressed.
Daniel A. Vorobiof, MD, of the Sandton Oncology Centre, and Bernardo Leon Rapoport, MD, of The Medical Oncology Centre of Rosebank, discuss the first study to evaluate the efficacy and safety of a single dose of intravenous fosaprepitant. The use of this NK1 inhibitor and another (rolapitant) in a second study discussed may change the management of chemotherapy-induced nausea and vomiting and improve quality of life for patients (Abstracts 9629 and 9615).
Charles F. von Gunten, MD, PhD, of OhioHealth Kobacker House discusses the ROMANA 1 and 2 trials on cachexia in NSCLC and a study on olanzapine vs fosaprepitant for the prevention of nausea and vomiting (Abstracts 9500 and 9502).
Philip Bonomi, MD, of Rush Medical College, summarizes the findings on anamorelin and its use in advanced NSCLC for improvement in anorexia/cachexia symptoms (Abstracts ORAL 29.01, ORAL 29.02).
Eduardo Bruera, MD, of The University of Texas MD Anderson Cancer Center, discusses exciting developments in the assessment and management of cachexia, as well as a number of emerging pharmacologic and nonpharmacologic interventions (Abstract 67).
Lorenzo Cohen, MD, of The University of Texas MD Anderson Cancer Center, discusses nonpharmacologic approaches to symptom control. Techniques such as acupuncture for managing pain and chemotherapy-induced nausea and vomiting, or yoga and meditation to help improve quality of life, can be safely integrated into oncology care.